Mazdutide Demonstrates Promising Weight Loss Results
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on July 4th, 2025
|
Many developing and recently developed countries, including Vietnam, are witnessing a rising prevalence of obesity. Glucagon receptor agonists—originally designed to manage type 2 diabetes—have shown potential in supporting weight loss. One such agent, mazdutide, was evaluated for its weight management effects in a study sponsored by Innovent Biologics.
This phase 3 clinical trial enrolled 610 participants in China who met the criteria for overweight or obesity. The average participant was 34.2 years old, with a mean body mass index (BMI) of 31.1. Participants were randomly assigned to receive weekly subcutaneous injections of either a placebo, 4 mg of mazdutide, or 6 mg of mazdutide. Mazdutide is a synthetic peptide that mimics glucagon and activates its receptor, promoting lipolysis and fatty acid oxidation.
After 32 weeks of treatment, the group receiving mazdutide experienced an average body weight reduction of 10% from baseline. In addition to weight loss, participants saw improvements in cardiometabolic markers, including reduced blood pressure, triglycerides, LDL cholesterol, and alanine aminotransferase levels. The authors noted that the BMI threshold for obesity in China differs from that used in Western countries, and that this study’s relatively young cohort distinguishes it from previous trials of glucagon receptor agonists.
This phase 3 clinical trial enrolled 610 participants in China who met the criteria for overweight or obesity. The average participant was 34.2 years old, with a mean body mass index (BMI) of 31.1. Participants were randomly assigned to receive weekly subcutaneous injections of either a placebo, 4 mg of mazdutide, or 6 mg of mazdutide. Mazdutide is a synthetic peptide that mimics glucagon and activates its receptor, promoting lipolysis and fatty acid oxidation.
After 32 weeks of treatment, the group receiving mazdutide experienced an average body weight reduction of 10% from baseline. In addition to weight loss, participants saw improvements in cardiometabolic markers, including reduced blood pressure, triglycerides, LDL cholesterol, and alanine aminotransferase levels. The authors noted that the BMI threshold for obesity in China differs from that used in Western countries, and that this study’s relatively young cohort distinguishes it from previous trials of glucagon receptor agonists.